Anees Chagpar, MD, discusses her presentation on neoadjuvant chemo for clinically node-negative (cN0) breast cancer that took place at the annual Miami Breast Cancer Conference.

Dr Hurvitz discusses the HER2CLIMB and HER2CLIMB-02 trials examining tucatinib's activity and safety in patients with HER2-positive metastatic breast cancer.

Mattea Reinisch, MD, highlights the final efficacy and safety results of the phase 3b, multi-center, open-label Ribecca trial for women with ER+, HER2- locally advanced or metastatic breast cancer,…

Dr Linden shares encouraging results from the AMEERA-1 trial of SAR439859 for ER+/HER2- metastatic breast cancer, presented at the virtual 2020 SABCS Annual Meeting.

"HDRT allows precise control over the delivered amount of radiation and limits the exposure of surrounding healthy tissue," explains Alison Calkins, MD, in this breast cancer commentary.

Alison Calkins, MD, discusses the use of partial breast radiation therapy (breast brachytherapy) for patients with local breast cancer.

Hope S. Rugo, MD, discusses the OS findings of 2 trials examining ribociclib plus endocrine therapy for advanced breast cancer and visceral metastases.

Julie Gralow, MD, discusses the findings of the phase 2 SWOG S1416 trial.